PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



A61K 31/495		97/03675
AUIX 511475	A1 (43) International Publication Date: 6 February 1997	7 (06.02.97)
 (21) International Application Number: PCT/EP9 (22) International Filing Date: 11 July 1996 (1 (30) Priority Data: 9514464.8 14 July 1995 (14.07.95) (71) Applicant (for all designated States except US): LA TOIRE GLAXO WELLCOME S.A. [FR/FR]; Vineuse, F-75116 Paris (FR). (72) Inventor; and (75) Inventor/Applicant (for US only): DAUGAN, Alain, Marie [FR/FR]; Laboratoire Glaxo Wellcome S.A. de Recherches, Z.A. de Courtaboeuf, 25, avenue de F-91940 Les Ulis (FR). (74) Agents: FILLER, Wendy, Anne et al.; Glaxo Wellcome Berkeley Avenue, Greenford, Middlesex UB6 0NN 	 (81) Designated States: AL, AM, AT, AU, AZ, BB, BU (CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, C IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, L' MD, MG, MK, MN, MW, MX, NO, NZ, PL, P SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UU VN, ARIPO patent (KE, LS, MW, SD, SZ, UC patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, C CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. 	G, BR, BY, JE, HU, IL, T, LU, LV, T, RO, RU, G, US, UZ, J), Eurasian (), European GR, IE, IT,
 (54) Title: USE OF CGMP-PHOSPHODIESTERASE INF. (57) Abstract The use of compounds of formula (I) (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1': 6,11pyrido[3,4-b]indole-1,4-dione, (3S, 6R, 12aR)-2,3,6,7,12,12a-hexahydro-2,3-dimethyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1': 6,13,4-methylenedioxyphenyl)-pyrazino[2',1': 6,13,4-methylenedioxyphenyl)-pyrazino[2',1': 6,13,4-methylenedioxyphenyl)-pyrazino[2',1': 6,13,4-b]indole-1,4-dione, and physiologically acceptable salts and solvates thereof, in the treatment of impotence.	BITORS TO TREAT IMPOTENCE R^{0} $($ R^{0} $($ R	(1)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	КР	Democratic People's Republic	SD	Sudan
CF	Central African Republic		of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
СН	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	ТJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan

Find authenticated court documents without watermarks at docketalarm.com.

DOCKET

Δ

R M

Δ

1

USE OF CGMP-PHOSPHODIESTERASE INHIBITORS TO TREAT IMPOTENCE

This invention relates to the use of tetracyclic derivatives which are potent and selective inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase (cGMP specific PDE) in the treatment of impotence.

Impotence can be defined as a lack of power, in the male, to copulate and may involve an inability to achieve penile erection or ejaculation, or both. More specifically, erectile impotence or dysfunction may be defined as an inability to obtain or sustain an erection adequate for intercourse. Its prevalence is claimed to be between 2 and 7% of the human male population, increasing with age, up to 50 years, and between 18 and 75% between 55 and 80 years of age.

Reports of well-controlled clinical trials in man are few and the efficacy of orally administered drugs is low. Although many different drugs have been shown to induce penile erection, they are only effective after direct injection into the penis, e.g. intraurethrally or intracavernosally (i.c.), and are not approved for 15 erectile dysfunction. Current medical treatment is based on the i.c. injection of claimed with vasoactive substances and good results have been phenoxybenzamine, phentolamine, papaverine and prostaglandin E₁, either alone or in combination; however, pain, priapism and fibrosis of the penis are 20 associated with the i.c. administration of some of these agents. Potassium channel openers (KCO) and vasoactive intestinal polypeptide (VIP) have also been shown to be active i.c., but cost and stability issues could limit development of the latter. An alternative to the i.c. route is the use of glyceryl trinitrate (GTN) patches applied to the penis, which has been shown to be 25 effective but produces side-effects in both patient and partner.

As a general alternative to pharmacological intervention, a variety of penile prostheses has been used to assist achievement of an erection. The short term success rate is good, but problems with infection and ischaemia, especially in diabetic men, make this type of treatment a final option rather than first-line therapy.

The compounds of the invention are potent inhibitors of cyclic guanosine 3',5'monophosphate phosphodiesterases (cGMP PDEs). GB 9514464.8, which is the priority document for the present application describes the syntheses of the compounds of the invention and their utility in impotence. WO95/19978, which

RM Find authenticated court documents without watermarks at docketalarm.com.

10

5

30

DOCKET


5

10

15

20

was unpublished at the priority date of the present application, also describes the syntheses of the compounds of the invention and their utility in other diseases associated with inhibition of cGMP PDEs. The compounds may be represented by the following general formula (I):



and salts and solvates (e.g. hydrates) thereof, in which:

R^o represents hydrogen, halogen or C₁₋₆ alkyl;

R¹ represents hydrogen, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, haloC₁₋₆alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkylC₁₋₃alkyl, arylC₁₋₃alkyl or heteroarylC₁₋₃alkyl,

R² represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic

ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and

 R^3 represents hydrogen or C₁₋₃ alkyl, or R^1 and R^3 together represent a 3- or 4- membered alkyl or alkenyl chain.

Suitable individual compounds of the invention for use in the treatment of erectile dysfunction include:

Cis-2,3,6,7,12,12a-hexahydro-2-(4-pyridylmethyl)-6-(3,4-methylenedioxyphenyl)pyrazino[2', 1': 6,1]pyrido[3,4-b]indole-1,4-dione;

Cis-2,3,6,7,12,12a-hexahydro-6-(2,3-dihydrobenzo[b]furan-5-yl)-2-methylpyrazino[2',1':6,1]pyrido[3,4-b]indole -1,4-dione;
Cis-2,3,6,7,12,12a-hexahydro-6-(5-bromo-2-thienyl)-2-methylpyrazino[2',1':6,1]pyrido[3,4-b]indole -1,4-dione;

DOCKET

Cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(4-methylphenyl)-

pyrazino[2',1':6,1]pyrido[3,4-b]indole -1,4-dione;

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-isopropyl-6-(3,4-methylenedioxyphenyl)pyrazino[2',1':6,1]pyrido[3,4-b]indole -1,4-dione;

- (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-cyclopentyl-6-(3,4methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole -1,4-dione;
 (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-cyclopropylmethyl-6-(4-methoxyphenyl)pyrazino[2',1':6,1]pyrido[3,4-b]indole -1,4-dione;
 (6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(3-chloro-4-methoxyphenyl)-2-methyl-
- 10 pyrazino[2',1':6,1]pyrido[3,4-b]indole -1,4-dione; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione; (6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(3,4-methylenedioxyphenyl)pyrazino[2', 1': 6,1] pyrido [3,4-b] indole-1,4-dione;
- 15 (5aR, 12R, 14aS)-1,2,3,5,6,11,12,14a-Octahydro-12-(3,4methylenedioxyphenyl)-pyrrolo[1",2" : 4',5']pyrazino[2',1' : 6,1]pyrido[3,4b]indole-5-1,4-dione;

Cis-2,3,6,7,12,12a-hexahydro-2-cyclopropyl-6-(3,4-methylenedioxyphenyl)pyrazino[2',1':6,1]pyrido[3,4-b]indole -1,4-dione;

20 (3S, 6R, 12aR)-2,3,6,7,12,12a-hexahydro-3-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole -1,4-dione;
 and physiologically acceptable salts and solvates (e.g. hydrates) thereof.

The specific compounds of the invention are:

(6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl) pyrazino[2',1':6,1]pyrido[3,4-b]indole -1,4-dione (Compound A); and

(3S, 6R, 12aR)-2,3,6,7,12,12a-hexahydro-2,3-dimethyl-6-(3,4methylenedioxyphenyl)-pyrazino[2',1' : 6,1]pyrido[3,4-b]indole-1,4-dione (Compound B);

and physiologically acceptable salts and solvates (e.g. hydrates) thereof.

30 Unexpectedly, it has now been found that compounds of formula (I), and in particular compounds A and B, are useful in the treatment of erectile dysfunction. Furthermore the compounds may be administered orally, thereby

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.